Cross-sectional Study to Establish the Point Prevalence of Serotype 19A Pneumococcal Nasopharyngeal Carriage of Fully Vaccinated Children Aged 13-48 Months 7 Years Following Introduction of PCV-13
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Streptococcal infections
- Focus Pharmacodynamics
- 17 Oct 2018 Planned End Date changed from 31 Dec 2018 to 31 Oct 2019.
- 17 Oct 2018 Planned primary completion date changed from 17 May 2018 to 30 Apr 2019.
- 13 Jul 2017 Status changed from not yet recruiting to recruiting.